Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Perfinity and Thermo Fisher Scientific Sign Co-Marketing Agreement

Published: Friday, June 14, 2013
Last Updated: Friday, June 14, 2013
Bookmark and Share
The agreement will see the companies co-market an automated protein sample preparation and analysis system.

This solution combines Perfinity's automated sample preparation platform with Thermo Fisher Scientific's liquid chromatography and mass spectrometry instrumentation. There are applications in biopharmaceutical process monitoring, protein drug development and biomarker discovery.

"Pharmaceutical manufacturers cannot wait for 24 hours to monitor the purity of each batch of protein-based product," said Robert Ellis, Perfinity Biosciences CEO. "When proteins oxidize, things can go bad quickly, and this is very costly. We developed our automated sample preparation platform to generate results quickly enough to let customers protect the value of each batch before it's too late. Now, with the Thermo Scientific LC and MS instruments, we offer a complete system from automated sample preparation through data reporting."

"A major goal at Thermo Fisher is to create efficiency and productivity throughout the biopharmaceutical value chain, and Perfinity's approach to in-process analysis meshes nicely with these plans," said Patrick Bennett, Thermo Fisher director of marketing, pharmaceutical industry.

Perfinity's sample preparation platform is an automated system that reduces the time required for the trypsin digestion step prior to mass spec analysis from approximately 18 hours using conventional techniques to less than two minutes. The proprietary three-column system is based on the company's trypsin columns, and also includes an automated workstation and software. Thermo Fisher is providing Thermo Scientific UltiMate 3000 UHPLC systems and a choice of Orbitrap-based hybrid or triple quadrupole mass spectrometers depending on customers' specific requirements.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
Zika Vaccine Candidates Show Promise
Two experimental vaccines have shown promise against a major viral strain responsible for the Brazilian Zika outbreak.
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Antibody Drug Shows Promise in HIV Treatment
Researchers are a step closer to an alternative HIV treatment that has the potential for lasting effects and less frequent dosing.
Flu Vaccine May Reduce Risk of Death For Type 2 Diabetes Patients
Researchers at Imperial College London have suggested that the vaccine may have substantial benefits for patients with long-term conditions.
Flu Vaccine May Reduce Death Risk of Type 2 Diabetes
New research suggests that a new flu vaccine may reduce probability of type 2 diabetes patients being hospitalised with stroke and heart failure.
Disrupting Tumour-Promotion in Humans
Researchers have modified an existing protein to represses a specific cancer-promoting ‘message’ within cells.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
Vaccine Strategy Targets Multiple Influenza Viruses
Scientists have identified vaccine-induced antibodies that can neutralize strains of influenza virus that infect humans.
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!